Professor Dame Pam Shaw, Professor of Neurology and Pro-Vice Chancellor for the Faculty of Medicine, Dentistry and Health at the University of Sheffield and Founding Director of the Sheffield Institute for Translational Neuroscience (SITraN), one of the world leading centers for motor neuron disease (MND) research.
Professor Shaw graduated in Medicine with 1st Class Honours from the University of Newcastle in 1979. She undertook her MRCP and Specialist Training in Neurology training in Newcastle. In 1988 she was awarded an MD with commendation for her work on the neurological complications of coronary bypass surgery.
After an intermediate fellowship award from the Wellcome Trust, she was awarded a Wellcome Senior Fellowship in Clinical Science which she held from 1991 to 2001, underpinning her program of work investigating molecular mechanisms of motor neuron injury and new therapeutic approaches in motor neuron disease.
In 1997 she was appointed Professor of Neurological Medicine at the University of Newcastle and in 2000 was appointed as Professor of Neurology at the University of Sheffield. As an undergraduate in Newcastle she was awarded the Stephen Scott; Gibb; Mary Gordon; Mona McNaughton and Phillipson Prizes/Scholarships.
Recent post-graduate awards include: Association of British Neurologists Sir Charles Symonds award (1991; 1996; 2001); American Academy of Neurology Sheila Essey award 2001; UK Royal College of Physicians Jean Hunter award 2006; the International ALS/MND Forbes Norris award 2007; Fellowship of the Academy of Medical Sciences 2007. In 2014 she was awarded the Dame Commander of the Order of the British Empire (DBE) for services to Neuroscience in the HM the Queen’s New Year’s Honours.
She has authored more than 400 publications of original research (Google Scholar H-index 82), reviews and book chapters and has edited several books on ALS/MND. Her research is funded by the Medical Research Council, the Wellcome Trust, NIHR, the MND Association, the European Union and biotechnology & pharmaceutical industry partners. Since 1983 she has generated more than £56m in research income.
Feom 2008 – 2015 she led the Clinical Studies Group for ALS/MND within the NIHR Dementia and Neurodegenerative Diseases (DeNDRoN) clinical research network which links 21 MND Care and Research Centres and has developed a network of 10 UK centres experienced in MND clinical trials. Prof. Shaw has taken part in more than 15 MND clinical trials, including roles as UK Chief Investigator and Steering Committee member and also including several academic led studies. She is an active member of the European Network for the Cure of ALS (ENCALS).